Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Machado-Neto 2018 Cell Death Dis

From Bioblast
Publications in the MiPMap
Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Rodrigues Alves APN, Scheucher PS, Simões BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, Traina F (2018) Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. Cell Death Dis 9:311.

» PMID: 29472557 Open Access

Machado-Neto João Agostinho, Fenerich Bruna Alves, Scopim-Ribeiro Renata, Eide Christopher A, Coelho-Silva Juan Luiz, Dechandt Carlos Roberto Porto, Fernandes Jaqueline Cristina, Rodrigues Alves Ana Paula Nunes, Scheucher Priscila Santos, Simoes Belinda Pinto, Alberici Luciane Carla, de Figueiredo Pontes Lorena Lobo, Tognon Cristina E, Druker Brian J, Rego Eduardo Magalhaes, Traina Fabiola (2018) Cell Death Dis

Abstract: The recurrent gain-of-function JAK2V617F mutation confers growth factor-independent proliferation for hematopoietic cells and is a major contributor to the pathogenesis of myeloproliferative neoplasms (MPN). The lack of complete response in most patients treated with the JAK1/2 inhibitor ruxolitinib indicates the need for identifying novel therapeutic strategies. Metformin is a biguanide that exerts selective antineoplastic activity in hematological malignancies. In the present study, we investigate and compare effects of metformin and ruxolitinib alone and in combination on cell signaling and cellular functions in JAK2V617F-positive cells. In JAK2V617F-expressing cell lines, metformin treatment significantly reduced cell viability, cell proliferation, clonogenicity, and cellular oxygen consumption and delayed cell cycle progression. Metformin reduced cyclin D1 expression and RB, STAT3, STAT5, ERK1/2 and p70S6K phosphorylation. Metformin plus ruxolitinib demonstrated more intense reduction of cell viability and induction of apoptosis compared to monotherapy. Notably, metformin reduced Ba/F3 JAK2V617F tumor burden and splenomegaly in Jak2V617F knock-in-induced MPN mice and spontaneous erythroid colony formation in primary cells from polycythemia vera patients. In conclusion, metformin exerts multitarget antileukemia activity in MPN: downregulation of JAK2/STAT signaling and mitochondrial activity. Our exploratory study establishes novel molecular mechanisms of metformin and ruxolitinib action and provides insights for development of alternative/complementary therapeutic strategies for MPN.

Bioblast editor: Kandolf G O2k-Network Lab: BR Ribeirao Preto Alberici LC

Labels: MiParea: Respiration, Genetic knockout;overexpression, Pharmacology;toxicology  Pathology: Cancer, Other 

Organism: Human, Mouse  Tissue;cell: Other cell lines  Preparation: Intact cells 

Coupling state: LEAK, ROUTINE, ET  Pathway: ROX  HRR: Oxygraph-2k 

Labels, 2018-04, Metformin